id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-253862-jl1zhg13	Khalaf, Khalil	SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment	2020-10-06		.txt	text/plain	14633	533	37	A cohort study Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Use of convalescent plasma therapy in SARS patients in Hong Kong Treatment with convalescent plasma for influenza A (H5N1) infection Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience Effectiveness of convalescent plasma therapy in severe COVID-19 patients Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients Severe acute respiratory syndrome coronavirus viroporin 3A activates the NLRP3 inflammasome The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China Biology of IL-38 and its role in disease IL-37 is a fundamental inhibitor of innate immunity Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19 (CoV-19 or SARS-CoV-2): anti-inflammatory strategies Baricitinib as potential treatment for 2019-nCoV acute respiratory disease Use of baricitinib in patients with moderate and severe COVID-19 Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, therapeutic potential Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19) Similar to SARS, infected patients presented with a variety of clinical courses, from mild upper respiratory symptoms to fulminant pneumonia and multi-organ system failure.	cache/cord-253862-jl1zhg13.txt	txt/cord-253862-jl1zhg13.txt
